Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Shares of Aprea Therapeutics, Inc. (APRE) have been struggling lately and have lost 11.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean ...

Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in ...

Explore Aprea Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for APRE. FDA clearance for Aprea Therapeutics' APR-1051 IND application, a promising ...

) has been revised to $4.49 / share. This is a decrease of 17.50% from the prior estimate of $5.44 dated March 25, 2026. The price target is an average of many targets provided by analysts. The latest ...

APRE have shared their latest single "Come Down", a humbling anthem that lands with a tender message. Commencing with APRE painting a 'doom and gloom' picture with echoing instrumentals that sound ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...